### Analysis

The earnings call for Amgen Inc. revealed a strong operating performance in 2012, with significant advancements in the company's pipeline and strategic acquisitions. The company's guidance for 2013 indicates a moderate growth trajectory, with revenues expected to be between $17.8 billion and $18.2 billion and adjusted EPS between $6.85 and $7.15. The management's focus on returning capital to shareholders through dividends and share repurchases was highlighted, with the dividend increasing by 31% for 2013 to $0.47 per share. The company's strategic initiatives, such as the acquisition of deCODE Genetics, were also emphasized. However, the call also mentioned potential challenges in the EPO and XGEVA markets, as well as the competitive landscape in the pipeline for 319. The management's cautious approach to the market and the focus on long-term growth opportunities suggest a balanced outlook.

### Conclusion

The short-term impact on the stock price is likely to be positive, driven by the strong operating performance, dividend increase, and strategic acquisitions. However, the cautious guidance for 2013 and the competitive challenges in certain markets may temper the immediate enthusiasm. Overall, the stock is likely to see a moderate positive impact in the next 1-2 weeks.

**Rating:** 1